Amicus Faces Shareholder Suit Over Rosy NDA Statements
Amicus Therapeutics Inc. misled investors about the prospects of a new drug to treat a rare genetic disease, then reversed course two weeks later and sent stock prices plummeting, a shareholder...To view the full article, register now.
Already a subscriber? Click here to view full article